Similar articles

• Cyclosporine and tacrolimus: the mainstay of immunosuppressive therapy for solid organ transplantation.

  Testa G, Klintmalm GB. Testa G, et al. Clin Liver Dis. 1997 Aug;1(2):417-37, x. doi: 10.1016/s1089-3261(05)70278-6. Clin Liver Dis. 1997. PMID: 15562576 Review.
• [Pro- and antitumor effects of the main immunosuppressive drugs used in the clinical practice of transplantation].

  Marchini F. Marchini F. G Ital Nefrol. 2007 Mar-Apr;24(2):171. G Ital Nefrol. 2007. PMID: 17458835 Italian. No abstract available.
• [Tacrolimus in kidney transplantation. Bürgenstock, Switzerland, 20 March 1998].

  [No authors listed] [No authors listed] Dtsch Med Wochenschr. 1998 Jul 10;123(28-29 Suppl):1-12. Dtsch Med Wochenschr. 1998. PMID: 9697633 German. No abstract available.
• TGF-beta expression in protocol transplant liver biopsies: a comparative study between cyclosporine-A (CyA) and tacrolimus (FK 506) immunosuppression.

  Mohamed MA, Burt AD, Robertson H, Kirby JA, Talbot D. Mohamed MA, et al. Transplant Proc. 2001 Feb-Mar;33(1-2):1378-80. doi: 10.1016/s0041-1345(00)02518-5. Transplant Proc. 2001. PMID: 11267336 No abstract available.
• Tacrolimus: a new immunosuppressive agent.

  Kelly PA, Burckart GJ, Venkataramanan R. Kelly PA, et al. Am J Health Syst Pharm. 1995 Jul 15;52(14):1521-35. doi: 10.1093/ajhp/52.14.1521. Am J Health Syst Pharm. 1995. PMID: 7552894 Review.